Seattle, WA -- (SBWIRE) -- 11/29/2019 -- Tularaemia is zoonosis disease of wide variety of wild birds and mammals. Humans are infected mainly through the bite of arthropods, particularly ticks and mosquitoes. Tularemia is an infectious disease caused by the gram negative bacteria known as Francisella tularensis. Tularemia occurs mainly in North America, Europe and Asia, a few cases are acquired in Australia. People can develop tularemia by breathing in the F. tularensis contaminated air and consuming F. tularensis contaminated drink or food or having contact with infected animals.

To Get Free Sample of This Research Report: https://www.worldwidemarketreports.com/sample/244528

Symptoms of Tularaemia includes joints and muscle aches, shortness in breathing, and chest pain, swollen lymph glands in the neck, headache, cough, etc. diagnosis of tularemia is usually done by the series of blood tests. tularaemia is mostly distributed in the Northern hemisphere and is not found in the southern hemisphere or tropics. According to the European centre for disease prevention and control, the number of human cases is approximately 800 annually. Antibiotics are usually given to the patients suffering from Tularaemia. Treatment usually last for 10 to 21 days depending upon the stage and medication given. According to CDC, 230 cases of tularaemia were reported in United States in 2016. Tularaemia is a rare disease which is difficult to diagnose and is usually mistaken with other common illness.

Antibiotic treatment for tularaemia is based on few drugs and development of novel therapeutic approaches in the recent years to improve the treatment pattern spur the market of Tularaemia in near future. Increasing incidence of tularaemia in various developed economies and developing economies significantly drive the Tularaemia market in the forecast period. Lack of effective and safe vaccine availability restraints the growth of tularaemia. Stringent regulation for the approval of drugs is one among the restraint which hinder the growth of Tularaemia market in near future.
Rising prevalence of Tularaemia in northern hemisphere and increased outbreak in various countries will drive the market of Tularaemia in the near future. Increasing awareness among the general population especially in United States and regions affected by tularaemia drive the market of Tularaemia in the forecast period. Research and development in developing novel drugs and approach will drive the market in near future.

The North America market for Tularaemia Market holds the largest revenue share, due to increasing incidence of tularaemia and increasing awareness among the people. Favourable reimbursement scenario and increasing adoption of new drug and increasing research and development drive the market of Tularaemia in North America.

Europe accounts for the second large revenue share in the global Tularaemia Market, owing to increasing prevalence of infection and increased number of reported cases and improved healthcare infrastructure. Asia Pacific is expected to witness slow growth, due to less incidence cases reported in this region. China is expected to register significant growth, owing to number of incidence cases. Latin America and Middle East Africa are projected to exhibit slow growth in Tularaemia Market, owing to lack of awareness among population and no cases reported in this region.

Examples of some of the key service provider present in the global Tularemia Market are Pfizer Ltd., Thermo Fisher Scientific Inc., Allergan, Bayer HealthCare Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Lupin Ltd., Apotex Inc., Teva Pharmaceutical Industries Ltd among others.

Else, Place an Inquire before Purchase: https://www.worldwidemarketreports.com/quiry/244528

Customisation of the Report
In case of any queries or customisation requirements please connect with our sales team, who will ensure that your requirements are met.